Sera (SERA)
Develops blood tests and predictive analytics for earlier assessment of spontaneous preterm-birth risk.
$2.17
vs last close+0.05 (+2.36%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | |
| Research & development | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | |
| Selling & marketing | 1 | 0 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 2 | 2 |
| General & administrative | 3 | 0 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Operating income | −8 | −9 | −9 | −9 | −9 | −9 | −9 | −9 | −9 | −9 | −9 | −10 |
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Interest income | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 |
| Income before tax | −7 | −8 | −8 | −8 | −8 | −9 | −8 | −8 | −8 | −8 | −8 | −9 |
| Net income from continuing operations | −7 | −8 | −8 | −8 | −8 | −9 | −8 | −8 | −8 | −8 | −8 | −9 |
| Net income | −7 | −8 | −8 | −8 | −8 | −9 | −8 | −8 | −8 | −8 | −8 | −9 |
| EPS, basic | −$0.23 | −$0.25 | −$0.25 | −$0.25 | −$0.24 | −$0.25 | −$0.20 | −$0.16 | −$0.16 | −$0.16 | −$0.17 | −$0.18 |
| EPS, diluted | −$0.23 | −$0.25 | −$0.25 | −$0.25 | −$0.24 | −$0.25 | −$0.20 | −$0.16 | −$0.16 | −$0.16 | −$0.17 | −$0.18 |
| Weighted average shares, basic | 31 | 31 | 32 | 33 | 34 | 34 | 42 | 49 | 50 | 50 | 50 | 50 |
| Weighted average shares, diluted | 31 | 31 | 32 | 33 | 34 | 34 | 42 | 49 | 50 | 50 | 50 | 50 |
| EBITDA | −7 | −8 | −8 | −8 | −8 | −8 | −8 | −8 | −8 | −8 | −8 | −9 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −7 | −8 | −8 | −8 | −8 | −9 | −8 | −8 | −8 | −8 | −8 | −9 |